S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz,Heinz Tüchler,Francesc Solé,Mar Mallo,E. Luño,José Cervera,Isabel Granada,Barbara Hildebrandt,Marilyn L. Slovak,Kazuma Ohyashiki,Christian Steidl,Christa Fonatsch,Michael Pfeilstöcker,Thomas Nösslinger,Peter Valent,Aristoteles Giagounidis,Carlo Aul,Michael Lübbert,Reinhard Stauder,Otto Krieger,Guillermo Garcia-Manero,Stefan Faderl,Sherry Pierce,Michelle M. Le Beau,John M. Bennett,Peter L. Greenberg,Ulrich Germing,Detlef Haase +27 more
TL;DR: A new and comprehensive cytogenetic scoring system based on an international data collection of 2,902 patients with primary MDS and oligoblastic acute myeloid leukemia (AML) after MDS treated with supportive care only is proposed, providing clear prognostic classification in 91% of all patients.
Journal ArticleDOI
Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Deborah A. Thomas,Stefan Faderl,Jorge E. Cortes,Susan O'Brien,Francis J. Giles,Steven M. Kornblau,Guillermo Garcia-Manero,Michael J. Keating,Michael Andreeff,Sima Jeha,Miloslav Beran,Srdan Verstovsek,Sherry Pierce,Laurie Letvak,August J. Salvado,Richard E. Champlin,Moshe Talpaz,Hagop M. Kantarjian +17 more
TL;DR: Outcome with hyper-CVAD and imatinib mesylate appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed.
Journal ArticleDOI
Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia
William G. Wierda,Susan O'Brien,Sijin Wen,Stefan Faderl,Guillermo Garcia-Manero,Deborah A. Thomas,Kim Anh Do,Jorge E. Cortes,Charles Koller,Miloslav Beran,Alessandra Ferrajoli,Francis J. Giles,Susan Lerner,Maher Albitar,Hagop M. Kantarjian,Michael J. Keating +15 more
TL;DR: FCR induced the highest CR rate reported in a clinical trial of previously treated patients with CLL, and molecular remissions were achieved in a third of patients achieving CR.
Journal ArticleDOI
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
Deborah A. Thomas,Stefan Faderl,Susan O'Brien,Carlos E. Bueso-Ramos,Jorge E. Cortes,Guillermo Garcia-Manero,Francis J. Giles,Srdan Verstovsek,William G. Wierda,Sherry Pierce,Jianqin Shan,Mark Brandt,Fredrick B. Hagemeister,Michael J. Keating,Fernando Cabanillas,Hagop M. Kantarjian +15 more
TL;DR: Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities composing 1% to 5% of non‐Hodgkin lymphomas NHL or ALL.
Journal ArticleDOI
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Guillermo Garcia-Manero,Hagop M. Kantarjian,Blanca Sanchez-Gonzalez,H. Yang,Gary L. Rosner,Srdan Verstovsek,Michael Rytting,William G. Wierda,Farhad Ravandi,Charles Koller,Lianchun Xiao,Stefan Faderl,Zeev Estrov,Jorge E. Cortes,Susan O'Brien,Elihu H. Estey,Carlos E. Bueso-Ramos,Jackie Fiorentino,Elias J. Jabbour,Jean Pierre J. Issa +19 more
TL;DR: This combination of epigenetic therapy in leukemia was safe and active, and was associated with transient reversal of aberrant epigenetic marks.